Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

68° Partly Cloudy

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2026

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.000 -0.030 (-2.91%)

Delayed Quote Updated: 2:42 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Lineage Provides Update on ReSonance® Program for Hearing Loss

October 29, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

September 08, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics (NYSEARCA:LCTX) Slips on Q2 Revenue Miss, but EPS In Line and Pipeline Advances ↗

August 06, 2026

Via Chartmill

Lineage Cell Therapeutics (NYSEARCA:LCTX) Q1 2026 Results: Revenue Miss and Increased Losses Weigh on Investor Sentiment ↗

May 12, 2026

Via Chartmill

Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss ↗

March 05, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

CEO outlines manufacturing scale-up strategy for cell therapies amid $50.8M cash runway.

Via The Motley Fool

Topics Earnings

Lineage Cell Therapeutics Q2 Earnings Call Highlights ↗

August 09, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type...

Via MarketBeat

Topics Earnings

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 06, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

July 30, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan ↗

July 14, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being...

Via MarketBeat

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

July 13, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 06, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call ↗

July 01, 2026

On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to...

Via Benzinga

Topics Earnings

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

May 20, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

Via FinancialNewsMedia

Lineage Cell Therapeutics Q1 Earnings Call Highlights ↗

May 15, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program...

Via MarketBeat

Topics Earnings

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

May 05, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

May 04, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Formation of Scientific Advisory Board

April 13, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

March 24, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 05, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

February 26, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

January 06, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Issues Letter to Stockholders

January 05, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 06, 2025

Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027.

Via Chartmill

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 06, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

October 30, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 22, 2025

Via Benzinga

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

September 08, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: editor@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

All News about Lineage Cell Therapeutics, Inc. Common Stock

Sections

Services

Follow Us